A departing director will stay with BetterLife Pharma as an adviser.

BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced Tony Pullen's resignation from its board, effective November 4, 2026, and his continued role as an advisor. Henry Chow, CPA, CA, was appointed as a new director. Pullen brought life sciences investment experience, while Chow has extensive public company audit experience. The company is developing BETR-001 for chronic cluster headache and chronic migraine.

Original reporting
Published Nov 5, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$BETRF
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Market read

Governance change with limited immediate market impact.

02

Timing

effective today

Relevance 5/10Novelty 5/10Timing: effective today

Background

Board member resignation and appointment at BetterLife Pharma, a Canadian biotech developing BETR-001.

Market effects

minimal effect on biotech sector

limited to Canadian market

none

Key entities

  • BetterLife Pharma Inc.

    Emerging biotechnology company listed on CSE (BETR) and OTCQB (BETRF).

  • Tony Pullen

    Resigned from board, remains advisor.

  • Henry Chow

    Appointed new director.

Related articles

MedAI 8/10

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

HighAI 8/10

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.

$SPCBMed

SuperCom Wins 2nd Electronic Monitoring Contract in Indiana, Fully Displacing Incumbent Provider

SuperCom (SPCB) won its second electronic monitoring contract in Indiana, replacing an incumbent provider. The deal involves deploying its PureSecurity suite, with rollout starting in December 2026. The company reported a trailing twelve-month EBITDA of approximately $12.1 million through Q3 2026, citing over 50 new U.S. contracts and 20 national project wins in Europe since mid-2024.